Arunabh Sekhri, MD
Hematology & Oncology · Springfield, NJNPI 1033442207
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (50.4%), other and education — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by Novartis at 52.7% of the total. Reporting peaked in 2021 at $1,184 and has fallen 92.5% since, to $89 in 2025. That places this record below the midpoint for hematology & oncology clinicians in NJ, where the typical reported total is $2,686.
Across 113 payments — averaging $25.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- Johnson & Johnson$145
- Merck$134
- AbbVie$119
- Amgen$114
- Daiichi Sankyo Inc.$71
- plus $783 from 29 others
What the payments were for
- Food & beverage$1,45550%
- Education$2007%
- Entertainment$171%
- Other$1,21242%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 32 | $1,519 |
| Johnson & Johnson | 4 | $145 |
| Merck | 9 | $134 |
| AbbVie | 8 | $119 |
| Amgen | 2 | $114 |
| Daiichi Sankyo Inc. | 5 | $71 |
| E.r. Squibb & Sons, L.L.C. | 5 | $68 |
| GSK | 4 | $56 |
| Seagen Inc. | 3 | $45 |
| AstraZeneca(2 entities) | 3 | $44 |
| Incyte Corporation | 3 | $44 |
| Dendreon Pharmaceuticals LLC | 2 | $43 |
| Sanofi | 2 | $37 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $35 |
| Boehringer Ingelheim | 2 | $30 |
| Astellas Pharma US Inc | 2 | $29 |
| Karyopharm Therapeutics Inc. | 2 | $29 |
| Eisai Inc. | 2 | $29 |
| Pfizer | 2 | $28 |
| Regeneron Healthcare Solutions, Inc. | 2 | $26 |
| Lilly USA, LLC | 2 | $26 |
| EMD Serono, Inc. | 2 | $26 |
| Macrogenics, Inc. | 1 | $19 |
| Spinal Elements, Inc. | 1 | $17 |
| Global Blood Therapeutics, Inc. | 1 | $15 |
| Array Biopharma Inc | 1 | $15 |
| Welch Allyn | 1 | $15 |
| Myovant Sciences Inc. | 1 | $14 |
| Lexicon Pharmaceuticals, Inc. | 1 | $14 |
| Jazz Pharmaceuticals Inc. | 1 | $14 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $13 |
| Rigel Pharmaceuticals, Inc. | 1 | $13 |
| Sun Pharmaceutical Industries Inc. | 1 | $13 |
| Ipsen Biopharmaceuticals, Inc | 1 | $12 |
| Kyowa Kirin, Inc. | 1 | $12 |
How this compares
$2,885 in reported general payments places this provider in the 50th percentile of 362 hematology & oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 53 | $40,314 |
| Anastrozole | 60 | $912 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 35 | $836 |
| Duloxetine Hcl | 13 | $467 |
| Dexamethasone | 38 | $397 |
| Ondansetron Hcl | 40 | $383 |
| Sucralfate | 15 | $343 |
| Prochlorperazine Maleate | 27 | $322 |
| Letrozole | 17 | $309 |
| Potassium Chloride | 20 | $228 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 19 | $166 |
| Famotidine | 18 | $122 |
| Gabapentin | 19 | $97 |
| LoperamideLoperamide Hcl | 12 | $89 |
| Prednisone | 16 | $28 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $28 | $40,31453 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 362 hematology & oncology providers in New Jersey.
Other hematology & oncology in Springfield
- Joshua StraussSpringfield$739K
- Ashish ShahSpringfield$394K
- Ashish KhotSpringfield$88K
- Maithili RaoSpringfield$29K
- Robert SpiegelWestfield$864K
- Amit PatelJersey City$770K
- Charles FarberMorristown$609K
- Michael ScolaMorristown$506K
- Eshan PatelSomerville$420K
- Arturo Loaiza-BonillaPennington$406K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.